Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1535837
This article is part of the Research Topic Herbal Medicine for the Treatment of Chronic Metabolic Diseases, Volume II View all 8 articles

Antidiabetic potential of aqueous extract of Ficus vallis-choudae Delile leaf in streptozotocin-induced type 1 diabetes in Wistar rats : in vitro and in vivo studies

Provisionally accepted
David MIAFFO David MIAFFO 1*Kolefer Kilenma Kolefer Kilenma 2Hamadjida Adjia Hamadjida Adjia 2Oulianovie Kamgue Guessom Oulianovie Kamgue Guessom 3Barthelemy Maidadi Barthelemy Maidadi 1Abba Talba Mahamad Abba Talba Mahamad 1Ernest Rodrigue Talla Ernest Rodrigue Talla 2Fidèle Ntchapda Fidèle Ntchapda 2
  • 1 University of Maroua, Maroua, Cameroon
  • 2 University of Ngaoundéré, Ngaoundéré, Adamawa, Cameroon
  • 3 University of Buea, Buea, Cameroon

The final, formatted version of the article will be published soon.

    Background: Ficus vallis-choudae Delile are empirically used in Africa to treat diabetes mellitus. The aim of this study was to evaluate the in vitro and in vivo antidiabetic potential of the aqueous extract of Ficus vallis-choudae leaf (EFV) in streptozotocin-induced type 1 diabetes in rats.In vitro antioxidant study of EFV was performed via the ferric reducing antioxidant power (FRAP) assay. Inhibition tests of α-amylase and α-glucosidase activity demonstrated the in vitro antidiabetic potential of EFV. Type 1 diabetes (T1D) was induced in male rats by intraperitoneal injection of streptozotocin (65 mg/kg). Then, diabetic rats were divided into groups (n = 5) and treated with glibenclamide (10 mg/kg) and EFV at doses of 110, 220, and 440 mg/kg. Inhibition percentage, mean inhibitory concentration (IC 50 ), blood glucose, insulinemia, lipid profile, oxidative stress parameters, and markers of hepatorenal function were assessed.Results: EFV has iron reducing power (IC 50 = 95.90 ± 3.30 µg/mL) and inhibitory effect on the activity of α-amylase (IC 50 = 202.93 ± 0.52 µg/mL) and α-glucosidase (IC 50 = 171.28 ± 1.21 µg/mL). EFV caused a significant decrease (p < 0.001) in glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol levels. There was also a notable increase (p < 0.001) in the homeostatic assessment model of beta cell function, insulinemia, and highdensity lipoprotein cholesterol levels. EFV significantly decreased (p < 0.001) alanine aminotransferase and aspartate aminotransferase activities, and urea and creatinine levels. EFV caused a decrease in the activities of catalase and superoxide dismutase, a reduction in reduced glutathione levels and an increase (p < 0.001) in malondialdehyde levels. Conclusion: EFV has hypoglycemic, antidyslipidemic, and antioxidant potentials; thus partly confirming its empirical use in the treatment of diabetes mellitus.

    Keywords: type 1 diabetes, Streptozotocin, Ficus vallis-choudae, Wistar Rats, in vitro, in vivo

    Received: 27 Nov 2024; Accepted: 02 Jan 2025.

    Copyright: © 2025 MIAFFO, Kilenma, Adjia, Guessom, Maidadi, Mahamad, Talla and Ntchapda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: David MIAFFO, University of Maroua, Maroua, Cameroon

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.